Latest Conference Articles

A clinical rheumatologist breaks down how the combination therapy can be used to treat uncontrolled gout.

The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.

Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.

Dr. Philip Mease explains the next steps for testing the efficacy and safety of upadacitinib for patients with psoriatic arthritis.

Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.

Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.

Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.

Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.

More patients maintain therapeutic response when treated concomitantly with methotrexate and pegloticase when compared to those who use pegloticase alone.

A team investigated data from trials of tofacitinib, adalimumab, and placebo.

Study drug also recently showed promise in treating psoriatic arthritis.

The safety profile is consistent with previous studies of the ixekizumab.

The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.

Remission and LDA rates generally increased over time in patients with psoriatic arthritis receiving tofacitinib.

The late-breaking data reveal the safety and efficacy of upadacitinib versus placebo and adalimumab.

Asian countries regularly see higher rates of SLE prevalence globally.

The incidence rate of serious infection events and opportunistic infections was higher among the upadacitinib 30 mg group than the 15 mg group.

The findings are based on data from a 24-week observation from an ongoing phase 3 PATERA study.

In a late-breaking abstract, investigators test nanoparticle treatment using in vivo models.

In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.

Patients report sustained improvements in pain and fatigue from taking ixekizumab every 2 or 4 weeks over 3 years.

The findings are important to understand treatment persistence and switch patterns in rheumatoid arthritis patients with poor prognostic factors in a real-world setting.

Dr. Gregg Silverman said identification of Ruminococcus gnavus could allow earlier diagnosis of lupus nephritis.

Findings suggest 5-10 mg of tanezumab significantly improve pain versus placebo in patients with chronic low back pain.

The results highlight a significant improvement in rheumatoid arthritis signs and symptoms for those who used upadacitinib over placebo and adalimumab.

In a study presented at EULAR, investigators find 14-3-3η baseline levels did not correlate with baseline mTSS.

In both DISCOVER trials, investigators find guselkumab effective against active psoriatic arthritis domains.

The treatment has already proven to reduce oral ulcers associated with Behcet’s syndrome.

Patients are unaffected by the switch from ADL-EU to ADL-PF.

How clinical data for the interleukin-targeting class will begin to dictate more treatement decisions and research progression.